Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Filament Health Corp. is a clinical-stage natural psychedelic drug development company focused on discovering, developing, and commercializing pharmaceutical-grade medicines derived from naturally occurring psychedelic compounds. The company operates within the biopharmaceutical and mental health therapeutics industries, with an emphasis on addressing unmet needs in conditions such as substance use disorders, depression, and other neuropsychiatric indications. Its core value proposition is the development of standardized, naturally sourced psychedelic drug candidates that are compatible with modern regulatory frameworks.
The company’s primary revenue drivers are currently research and development activities rather than commercial sales, as Filament Health remains pre-revenue and focused on clinical advancement. Its strategic positioning centers on proprietary intellectual property covering extraction, purification, and formulation of natural psychedelics, which differentiates it from peers pursuing fully synthetic compounds. Filament Health was founded in 2020 and became publicly listed in Canada shortly thereafter, evolving rapidly through the acquisition of specialized laboratories and the expansion of its clinical pipeline.
Business Operations
Filament Health operates through an integrated research and development model encompassing drug discovery, formulation, and clinical trial execution. Its principal business activities include the development of natural psychedelic drug candidates such as botanical psilocybin and botanical MDMA, which are produced under Good Manufacturing Practice (GMP) conditions. The company generates value by advancing these candidates through preclinical and clinical stages with the goal of regulatory approval.
Operations are conducted primarily in Canada and the United States, supported by in-house laboratory infrastructure and controlled manufacturing processes. A key operational asset is Psilo Scientific Ltd., a wholly owned subsidiary that houses the company’s extraction and analytical laboratories. Filament Health collaborates with academic institutions, clinical research organizations, and government-approved trial sites to conduct human studies under applicable regulatory approvals.
Strategic Position & Investments
Filament Health’s strategic direction is centered on becoming a leading supplier of natural psychedelic drug candidates for regulated medical use. Growth initiatives include expanding its intellectual property portfolio, advancing multiple compounds through clinical trials, and pursuing indications with clear regulatory pathways such as substance use disorders. The company has invested heavily in clinical research programs designed to demonstrate bioequivalence, safety, and efficacy of natural psychedelic formulations compared with synthetic counterparts.
The company has not reported large-scale transformative acquisitions but has made targeted investments in laboratory infrastructure and proprietary processing technologies. Its portfolio includes multiple active and planned clinical trials involving botanical psilocybin and botanical MDMA. Filament Health is also involved in emerging areas of psychedelic medicine, including drug-microbiome interactions and novel delivery formats, where permitted by regulation.
Geographic Footprint
Filament Health is headquartered in Canada, with its corporate base in British Columbia. The company’s primary laboratory and research operations are also located in Canada, where it benefits from a comparatively advanced regulatory environment for psychedelic research. Canada represents the core hub for manufacturing, intellectual property development, and early-stage clinical coordination.
Internationally, Filament Health maintains a meaningful operational presence in the United States, where it conducts and supports FDA-authorized clinical trials and works with U.S.-based research partners. While the company does not yet operate commercial facilities across multiple continents, its regulatory strategy and intellectual property filings are designed to support future expansion into North America and other jurisdictions with evolving psychedelic medicine frameworks.
Leadership & Governance
Filament Health is led by an executive team with experience in biotechnology, life sciences, and regulated drug development. The leadership emphasizes scientific rigor, regulatory compliance, and long-term value creation through defensible intellectual property and clinical validation.
Key executives include:
- Benjamin Lightburn – Chief Executive Officer
- Dr. Joshua Woolley – Head of Clinical Research
- Dr. Chris Batty – Chief Science Officer
- Timothy McAuley – Chief Financial Officer
The company’s governance framework aligns with public company standards in Canada and the United States, with oversight focused on capital discipline, regulatory adherence, and transparent clinical development milestones.